B7‑H3‑Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
ARTEMIS-008 met its primary endpoint, showing overall survival superiority over topotecan in relapsed extensive-stage SCLC
The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival for patients with relapsed extensive‑stage small‑cell lung cancer (SCLC) treated with the B7‑H3‑targeted ADC risvutatug rezetecan compared with the current standard‑of‑care chemotherapy, topotecan.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells